Hamartomatous polyposis syndromes by Zoran Stojcev et al.
Stojcev et al. Hereditary Cancer in Clinical Practice 2013, 11:4
http://www.hccpjournal.com/content/11/1/4REVIEW Open AccessHamartomatous polyposis syndromes
Zoran Stojcev1,2, Pawel Borun3, Jacek Hermann4, Piotr Krokowicz5, Wojciech Cichy6, Lukasz Kubaszewski7,
Tomasz Banasiewicz4 and Andrzej Plawski3*Abstract
Hamartomas are tumour-like malformations, consisting of disorganized normal tissues, typical of the site of tumour
manifestation. Familial manifestation of hamartomatous polyps can be noted in juvenile polyposis syndrome (JPS),
Peutz-Jeghers’ syndrome (PJS), hereditary mixed polyposis syndrome (HMPS) and PTEN hamartoma tumour
syndrome (PHTS). All the aforementioned syndromes are inherited in an autosomal dominant manner and form a
rather heterogenous group both in respect to the number and localization of polyps and the risk of cancer
development in the alimentary tract and other organs. Individual syndromes of hamartomatous polyposis
frequently manifest similar symptoms, particularly during the early stage of the diseases when in several cases their
clinical pictures do not allow for differential diagnosis. The correct diagnosis of the disease using molecular
methods allows treatment to be implemented earlier and therefore more effectively since it is followed by a strict
monitoring of organs that manifest a predisposition for neoplastic transformation.
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The term of hamartoma corresponds to a non-neoplastic
tumour, consisting of disorganized normal tissues, typical
of the site of tumour manifestation. The term was intro-
duced by the German pathologist, Eugen Albrecht in
1904 [1]. Familial manifestation of hamartomatous polyps
can be noted in a number of morbid syndromes. The
diseases include juvenile polyposis syndrome (JPS), Peutz-
Jeghers’ syndrome (PJS), hereditary mixed polyposis syn-
drome (HMPS) and PTEN hamartoma tumour syndrome
(PHTS). It has also been suggested that the complex
includes, i.a., Cowden’s syndrome (CS), Bannayan-Riley-
Ruvalcaba syndrome (BRRS), Proteus’es syndrome (PS).
All the aforementioned syndromes are inherited in the
autosomal dominant manner and are conditioned by mu-
tations in four genes (Table 1). Besides the manifestation
of hamartomatous polyps in the alimentary tract these
infrequent syndromes are characterized by an increased
risk of neoplastic transformation. Development of neo-
plastic lesions is not restricted to the gastrointestinal
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reproduction in any medium, provided the orof neoplastic lesions in polyps of the type has not been
fully recognized but the involved mechanism of neo-
plastic transformation is distinct from that documented
in adenomas (Table 2).
Individual syndromes of hamartomatous polyposis fre-
quently manifest similar /symptoms, particularly during
the early stage of the diseases when in several cases their
clinical pictures do not allow for a differential diagnosis
[2]. The correct diagnosis of the disease using molecular
methods allows treatment to be implemented earlier and
therefore more effectively since it is followed by a strict
monitoring of organs that manifest a predisposition for
neoplastic transformation [3].Juvenile polyposis
Juvenile polyposis (MIM # 174900) is a rare disease
inherited in an autosomal dominant manner, described
by McColl in 1966 [4]. It occurs at an incidence of 1 per
100,000 births [5]. In most of the recorded cases juvenile
polyposis manifests a familiar involvement. Its diagnosis
is based on the detection of polyps, histopathologically
defined as juvenile polyps. Juvenile polyps are character-
ized by hyperplasia of mucous glands, retention cysts
accompanied by oedema, emboli in gland openings, rich
lamina propria of the mucosa with an absence of smoothLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Genes preconditioning syndromes of hamartomatous polyposis
Gene BMPR1A SMAD4 PTEN STK11
Name Bone morphogenetic protein receptor,
type Ia
Mothers against decapentaplegic,





Function of the protein receptor signalling protein phosphatase kinase
MIM *601299 *600993 *601728 *602216
Chromosome 10q22.3 18q21 10q23.31 19q13.3
Size 168.5 kbp 38.5 kbp 108 kbp 23 kbp
Exons 13 11 9 10
Amino acids 532 552 403 433
Transcript (bp) 3613 8365 9007 3276
Mass of protein 60 kDa 60 kDa 47 kDa 48.6 kDa
An asterisk (*) before MIM entry number indicates a gene.
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stroma (Table 3) [6]. The diameter of the polyps ranges
between 1 millimeter and a few centimeters. Polyps most
commonly occur in the large bowel and the anus (80%),
although they can appear in the upper part of the digestive
tract, in the stomach and in the small bowel. Single polyps
are manifested in 75% of the patients but the occurrence
of multiple juvenile polyps can also be noted. In respect
to the number of polyps, variability can be noted even
in members of a single family. Single juvenile polyps are
detected in around 2% of children and adolescents but
they display no malignant potential [7]. On the other
hand, among patients with juvenile polyposis the risk of
malignancy is much higher: according to various papers
on the subject it ranges from nine to over fifty percent
of the cases.
Juvenile polyposis is diagnosed according the following
criteria [8]:
– at least 3 polyps detected on colonoscopy
– juvenile polyps in the entire digestive tractTable 2 Risk of neoplastic disease manifestation in individual













Testes– in cases of family history of the disease any number
of juvenile polyps.
Three categories of the disease are distinguished [9,10]:
– juvenile polyposis of infants
– juvenile polyposis of the large bowel
– general form of juvenile polyposis.
The difference between juvenile polyposis of the large
bowel and the general form of juvenile polyposis depends
on the localization of the polyps. It is estimated that in
over 20% patients with JPS inborn errors are detected in
various organs. In the alimentary tract Meckel’s diverticula
with umbilical fistula andmalrotation of small intestine
have been detected. Cases of undescended testes, unilat-
eral renal agenesia and split uterus were diagnosed in
the urogenital system. Inborn errors in the chest include
a defect in the interatrial septum, arterionevous haem-
angiomas, stenosis of the pulmonary valve, Fallot’s
tetralogy, aortal stenosis, and persisting arterial duct.organs in cases of hamartomatous polyposis syndromes
ment in individual syndromes of hamartomatous polyposis
Peutz - Jeghers` syndrome PHTS
3-10











Table 3 Diagnostic criteria for recognising hamartomatic polyposities [8,47]
Syndrome of hamartomatous polyposities Diagnostic criteria
Juvenile polyposis • Numerous juvenile polyps (at least 3) in the large bowel and the rectum
• Any number of juvenile polyps in patients with familial course of the disease
• Juvenile polyps outside the colon (in the stomach or the small bowel) [8].
Peutz–Jeghers syndrome • Three or more histologically confirmed polyps
• Any number of polyps characteristic of PJS in patients with a burdened family anamnesis
• Typical melanotic dermomucosal lesions in patients with a burdened family anamnesis
• Any number of polyps typical for PJS and typical melanotic dermomucosal lesions





• Lesions in mucous membranes
Major criteria:
Breast cancer
Thyroid carcinoma (particularly follicular)




Other thyroid lesions (e.g. enlargement of thyroid gland)




Cancers of urogenital organs
Syndrome of mixed polyposity Lack of defined diagnostic criteria for the syndrome
Diagnosis is based on manifestation of numerous polyps of a variable histopathological type
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rachischisis were found within the central nervous system.
Moreover, osteomas, mesenteric haemangiomas, inherited
teleangiectasias, hypertelorism, inborn amniotony, super-
numerary toes and acute intermittent porphyria have
also been seen.
The manifestation of juvenile polyposis is preconditioned
by mutations in SMAD4 and BMPR1A genes [5,11,12].
Gene BMPR1Ac (OMIM *601299; Bone Morphogenetic
Protein Receptor, Type IA) resides in chromosome 10, in
q22-23. The gene consists of 11 exons. It codes for a
protein of 532 amino acids, belonging to the family of
TGF-β/BMP, representing a type I receptor with proper-
ties of serine-threonine kinase [13]. The transcript of
BMPR1A gene includes 3,613 nucleotides [14,15]. It
undergoes expression in almost all tissues including the
skeletal muscles, less intensely in the heart and placenta.
The SMAD4 (OMIM*600993, mothers against
decapentaplegic, drosophila, homolog of, 4) gene is
located in chromosome 18, in the region of q21.1. Itconsists of 11 exons. The genomic sequence of the
gene includes 50 thousand base pairs and its respective
mRNA consists of 3,197 nucleotides. It codes for a pro-
tein including 552 amino acids. SMAD4 is a suppressor
gene and it participates in the passage of a signal along
the pathway of transforming growth factor β (TGF β)
and its ligands [13]. SMAD4 is included among the
“common” SMAD, it contains two conserved domains
of MH1 and MH2 (Mad Homology domain). The amine
terminus of the SMAD terminus ends with an MH1
hair-pin domain, demonstrating DNA-binding activity.
The carboxy terminus of SMAD proteins ends with a
strongly conserved domain of MH2. It is responsible for
interaction with proteins involved in the translocation
of the complex to cell nucleus and interaction with
DNA-binding cofactors [16]. The linker of Co-SMAD
contains a leucine-rich NES (nuclear export signal) rec-
ognized by CMR1. Interaction of SMAD4 with phos-
phorylated Co-SMAD masks NES, protecting SMAD4
from recognition by CMR1 and from export to the cell
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sociation of the complex allows SMAD4 to be exported .
The import of SMAD proteins to the cell nucleus de-
velops with no involvement of nuclear transport factors.
Such an importin-independent transport has also been
described in cases of components participating in other
transformations, e.g. in the case of β-kateniny along the
pathway of Wnt. This is possible due to the direct inter-
action of SMAD with nucleoporins, mediated by inter-
action of the hydrophobic corridor in the MH2 domain
with the region of FG repetitions in nucleoporins [17].
The phosphorylated SMAD bind with Co-SMAD, i.e.
SMAD4. The complex formed in this way passes to the
cell nucleus where it becomes involved in the control of
expression including several genes, as either positive or
negative regulators of the alterations [18,19]. Activation
as well as repression requires the participation of the
same SMAD proteins while cell-specific interaction with
factors serving as coactivators or corepressors shapes
the appropriate response. The complex of SMAD4 with
R-SMAD binds to DNA through the MH1 domain, recog-
nizing the palindrome DNA sequence of GTCTAGAC.
Such an SMAD-binding sequence (SBE) is frequently
noted in genes which undergo expression in the presence
of TGF β/BMP ligands. GTCTAGAC SBE is present, on
average, in every 1,024 base pairs in the genome or at least
one such sequence can be noted in a control region of
every moderate size gene [17]. The literature of the subject
describes three mechanisms in which transcription can
be modified by SMAD and other transcription factors
acting on a promotor or enhancer [16]. The first
mechanism involves binding of the active R-SMAD
and Co-SMAD complex to a transcription factor and
such a multi-molecular complex binds to a recognized
sequence of DNA. Another mechanism involves the
separate binding of SMAD and a cofactor to DNA; the
interaction of the two proteins stabilizes the enhancer
properties. The last manner of control includes the in-
dependent () binding of SMAD and the additional factor
to a specific site of DNA. They act separately but in a
synergistic manner.
Mutations in the SMAD4 gene have been noted in
around 20% of patients with familial juvenile polyposis
[11,20] while a similar incidence of mutations has been
detected in the BMPR1A gene. In these genes over 120
mutations have been detected as leading to the develop-
ment of polyps linked to juvenile polyposis syndrome.
The mutations include first of all, small alterations, point
mutations and small deletions. Nevertheless, a high pro-
portion of alterations detected in patients with juvenile
polyposis also involve extensive lesions. Large deletions
were observed in the region of q22-q23 of chromosome
10. The alterations affected the two neighbouring genes
of PTEN and BMPR1A. Mutations in these genes areengaged in the development of distinct syndromes of
hamartomatous polyposis.
The mutations that have been described so far are of a
heterogenous character, with the exception of a single
mutation c.1244_1247delAGAC in exon 9 of the SMAD4
gene. This mutation is located in a hot spot, a region
containing four binucleotide repetitions of AG, where
the looping off of a DNA strand fragment probably takes
place, which undergoes a deletion.
Certain correlations were detected between phonotype
and genotype in JPS patients carrying a mutation in the
SMAD4 gene, who were found with higher frequency
to carry large polyps in their stomachs. Germ-line mu-
tations in the SMAD4 gene are responsible for a more
aggressive phenotype of juvenile intestinal polyposis,
manifesting itself in the form of a vascular malforma-
tion within sublayer components when the mutation
was located before the codon of 423. It was also noted
that polyps with mutation in the SMAD4 gene are
detected in both upper and lower parts of the digest-
ive tract while polyps with mutations in BMPR1A gene
are restricted to the rectum and the anal canal.
Peutz-Jeghers` syndrome
Peutz - Jeghers syndrome (PJS; OMIM 175200) is inherited
in an autosomal dominant way. The first description
of the syndrome was published by L.A.Peutz in 1921,
28 years later H. Jeghers described the clinical presen-
tation of the disease in detail. The first signs in the
form of hamartomatous polyps and pigment skin lesions
appear in childhood. Incidence of the syndrome ranges
from 1/29,000 to 1/120,000 births. The polyps appear
during the second or third decade of life in 80-100% of
patients. They may be located all along the alimentary
tract although the frequency of their manifestation is
variable and depends on localization within the digestive
tract (Table 3). They are most frequently detected in
the small bowel (96%), followed by those in the colon
and the stomach. In histopathology they are present as
tree-resembling branches of smooth muscle bundles.
The core of the polyps is formed by connective tissue
and smooth muscles. The entire lesion is covered by
normal looking epithelium. In the patients benign polyps
were detected outside the digestive tract, in the nose, the
respiratory tract, the gallbladder and the urinary bladder.
They are multiple and their size ranges from 1 to 3 cm.
The risk of developing intestinal cancer in patients with
Peutz – Jeghers` syndrome is slighly higher than that in
the general population. However, it should be noted that
hamartomatous polyps, particularly multiple ones, may
result in several complaints from the digestive tract.
They may cause ileus (due to intussusception) and
bleeding from the lower part of the tract, due to the ease
of polyp autoamputation [21,22]. Papers on patients
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extraintestinal malignancies [23,24]. An elevated risk
was noted for development of cancers in the pancreas,
the breasts, the ovary and the uterus [25]. Another char-
acteristic sign of the disease is the development of
muco-cutaneous melanosis, which appears in infancy or
in early childhood. The dark-brown, black or blue spots
of 1–5 mm in size are manifested in over 90% of patients.
They may develop around the mouth, the nostrils, the
eyes, the cheeks, on the tongue or the palate. Cases were
also described in which melanosis appeared on the hands,
feet, around the umbilicus or in the perianal region. Fol-
lowing pubescence and during adulthood the spots may
turn pale. Diagnosis of Peutz Jeghers` polyposis is based
on clinical signs, in cases of patients with a familial
manifestation of the disease the criteria for diagnosis
are restricted to the detection of melanin deposits. In
the absence of familial anamnesis it is necessary to
confirm the manifestation of at least two hamartomatous
polyps.
Peutz - Jeghers syndrome is preconditioned by the
manifestation of mutations in the STK11 (OMIM*602216
Serine/Threonine Protein Kinase 11) gene, located in the
short arm of chromosome 19, in the 13.3 region. The
gene consists of 10 exons, of which 9 code for a protein.
It undergoes comprehensive expression during embry-
onal development but also in the organs of adults, par-
ticularly in the pancreas, the liver and skeletal muscles.
The STK11 protein consists of three main domains, the
N-terminal non-catalytic domain with two signals for
nuclear localization, the highly conserved kinase do-
main and the regulatory domain at the carboxy end.
The kinase domain of this 433 amino acid protein is
located between the 49th and 309th amino acid. The
STK11 protein contains a few sites which undergo
phosphorylation and prenylation and the nuclear localization
signal (NLS). Due to the activity of kinases serins are
phosphorylated at positions of 31 and 325 and threonine
at position 363. STK11 is also capable of undergoing phos-
phorylation on threonins at positions 185, 189, 336, and
on serine at position 402. Autophosphorylation of STK11
at position Thr189 is very important for kinase activity
of the protein. On the other hand, the prenylation
motive of Cys430-Lys-Gln-Gln433 is positioned at the
carboxy terminus of the protein. Loss of STK11 protein
function precipitates the development of various defects.
This reflects the fact that the STK11 protein is involved in
a number of important cellular processes. In Xenopus, a
homologue of the STK11 gene, XEEX1, is engaged in the
process of early embryonal development. On the other
hand, mice lacking the STK11 gene die at around the 8th
day of embryogenesis. In the case of STK11+/− mice,
manifestation of polyps is observed, which in histopath-
ology are very similar to those noted in PJS. Molecularanalysis showed that loss of a single STK11 allele is suffi-
cient for the development of the polyps. Following the
45th week of life in >70% male STK11+/− mice and in
20% female STK11+/− mice histopathologically variable
types of liver malignancies are seen. The cancer cells
showeda loss of both STK11 [26,27]. STK11 was found to
control the TGF β pathway, forming a complex with the
SMAD4 protein through LIP1. LIP1 forms a specific
bridge between the two proteins [28]. STK11 also inter-
acts with the PTEN protein [29]. Moreover, STK11 kin-
ase participates in p53-dependent apoptosis.
Germ-line mutations of STK11 have been detected in
70% patients with an inherited form of the disease. In
cases of patients with negative anamnesis` detectability
of the mutations approximates 50% [30]. In the STK11
gene over 230 mutations have been described so far, in-
cluding 70 point mutations. A significant portion of the
mutations include small deletions (54) and small inser-
tions (33). Nevertheless, large deletions, including in-
dividual exons or even deletions of the entire gene are
also frequent in patients with PJS [31].
Cowden’s syndrome
Cowden’s syndrome (OMIM #158350; or Cowden Disease;
CD) is a very rare syndrome of hamartomatous polyposis.
Its incidence is estimated at 1 per 200,000 deliveries. Its
typical trait involves various hamartomatous lesions in
tissues originating from three germ layers: the endo-
derm, ectoderm and mesoderm. Apart from the gastro-
intestinal region (71% of the patients), the lesions are
manifested in the skin, mucous membranes and other
organs. An international consortium dealing with Cowden’s
syndrome evaluated a diagnostic criteria, which includes
dermomucosal lesions, including fibromas of the oral cavity
and papillary and hyperkeratotic alterations on the
face and extremities [32]. In almost 99% of patients
dermomucosal lesions develop before the 30th year of
age. Within the alimentary tract hamartomatous lesions
develop all along the tract, being most frequent in the
stomach, the colon and the oesophagus [33]. In the
oesophagus they appear as glycogenic keratinization. In
this syndrome hamartomatous lesions include, first of
all, polyps, adipomas and gangliomas [34,35]. In Cowden’s
syndrome polyps are distinguished by the presence of
nerve elements, not seen in the other syndromes of
hamartomatous polyposis. Moreover, in patients with
Cowden’s syndrome defects of the central nervous sys-
tem, such as macrocephaly (38%), mental retardation,
Lhermitte-Dulclos disease (LDD) and cerebellar gangiomas
can be detected. Defects of eyes and arterio-venous devel-
opmental lesions are also noted [36-38]. Defects of bones
in the skull, the spinal column and the hands trouble every
third patient. Patients with the syndrome are burdened
with an increased risk of developing benign or malignant
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retina, the breasts, the uterus and the skin. Breast cancers
are detected in 30% to 50% of women with Cowden’s
syndrome and in 25% the cancer is bilateral. In such
patients breast cancer develops at the very young age,
approximately 10 years earlier than in the general
population [36]. The risk of developing thyroid cancer
in women and men with Cowden’s syndrome is 10%
higher than in the general population. In respect to
histopathology the most frequent thyroid cancer in
patients with Cowden’s syndrome is papillary or follicular
but individual cases were also noted of medullary thyroid
carcinoma [39]. The PTEN (OMIM*601728; Phosphatase
And Tensin Homolog; PTEN) gene, responsible for the de-
velopment of Cowden’s syndrome was mapped in 1997 on
chromosome 10, region q23. This is a suppressor gene,
coding for a protein consisting of 403 amino acids,
representing a phosphatase responsible for the removal
of phosphate groups from molecules. Definition of PTEN
crystalline structure showed that the N-terminal domain
of the phosphatase strictly adheres to the C2 domain at
its carboxy terminus. The two domains create a basic
catalytic unit, encompassing the almost entire peptide
sequence of the protein, with the exception of the small
tail in the N-terminal portion of the protein and a lon-
ger 50 amino acid-fragment at the carboxy terminus.
The domain of phosphatase and C2 creating the cata-
lytic core of the protein are sufficient for its normal
function. The remaining parts seem to be involved in
the control of activity and/or interaction of PTEN with
the other molecules [40]. PTEN can de-phosphorylate
both proteins and lipids of cell membrane. It removes
the phosphate group from inositol ring position D3,
from 3,4,5 phosphatidylinositol triphosphate and 3,4
phosphatidylinositol diphosphate, produced during the
transmission of cellular signals through the activity of
phosphoinositol 3' kinase (PI3K) [41]. PTEN acts as a
specific switch-off for signal transmission along the
PI3K pathway, and in this way stops the cell cycle at the
G1 phase. The activity of the PTEN gene, involving
antagonization of phosphoinositol 3’ kinase action,
inhibits the activity of multiple oncoproteins exerting
their effect through the PI3K kinase. PTEN-PI3K controls
fundamental cellular processes linked to the mechanism
of neoplastic transformation. PTEN participates in the
control of the cell cycle through Akt kinase. Among
substrates of Akt kinase which play a significant role in
the cell cycle transcriptional factors such as FKHR
(Forkhead transcription factor), AFX, FKHRL1 or GSK3
can be distinguished. PTEN also controls cell divisions.
In pten−/− fibroblasts the response to stimulation of
apoptosis is lowered due to the augmented transcription
of proapoptotic genes, i.e. FAS and Bim. The activity of
PTEN protein phosphatase leads to the inhibition ofFAK (Focal Adhesion Kinase), responsible for cellular
adhesion and the capacity of cells to migrate [42]. PTEN
protein plays also an important role in the process of
angiogenesis and participates in control over the mTOR
pathway. In D. melanogaster loss of the dpten gene
function results in an increased size of cells and organs
while overexpression of dpten in yeasts causes an in-
verse phenotypic effect. In the case of mice loss of the
pten gene in neurons leads to the development of a set
of traits resembling those present in Lhermitte-Duclos
disease, representing one of the clinical presentations of
Cowden’s syndrome [43].
Somatic mutations in the PTEN gene lead to the de-
velopment of a number of various neoplasms. They are
detected in 80% of patients with Cowden’s syndrome.
Mutations in the PTEN gene are also detected in other
syndromes of hamartomatous polyposity, among others
in Bannayan-Riley-Ruvalcaba’s syndrome. The frequency
of lesions being detected in the PTEN gene approaches
60%. In the computer base of mutations 208 mutations
are described in the PTEN gene, of which the majority
involved mutations of altered sense and nonsense mu-
tations (87 mutations), small deletions and insertions
(75 mutations) [44]. In patients with Cowden’s syndrome
mutations in the PTEN gene are noted in the promoter
region while deletions of a portion or entire gene are
commonly observed in patients with Bannayan-Riley-
Ruvalcaba’s syndrome.
Hereditary mixed polyposis syndrome
The morbid unit (MIM #610069, Hereditary Mixed
Polyposis Syndrome, HMPS) first appeared in literature
in 1971: the case was described of an 11-year-old girl
with juvenile polyps and adenomas in the colon and
small intestine. However, it was not until 1987 that
Sarles suggested the term of mixed polyposis describing
the cases of a father and son with numerous various
types of polyps in the colon. In the father they included
metaplastic polyps and adenomas, in the son juvenile
polyps were additionally diagnosed. In the most accurate
way clinical traits of mixed polyposity syndrome were
presented in a family of a few generations, termed SM96
[45,46]. Among more than 200 members of the family
42 individuals demonstrated the presence of various
types of polyps, ranging from tubular adenomas, papil-
lary adenomas, flat adenomas to hyperplastic polyps and
atypical juvenile polyps. Histologically, the atypical ju-
venile polyps carried traits of hyperplastic polyps and of
adenomas. Colonoscopic tests were used to demonstrate
more than ten polyps in the colon and the anus. The
average age of the patients diagnosed with HMPS in the
SM96 family was 40 years.
Cao presented two three-generational families with a
course of the disease very similar to that of the SM96
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large bowel. In those family members Cao noted no
extraintestinal lesions.
Individuals with HMPS were found to manifest an
augmented predisposition to the development of malig-
nancies in the large bowel.
The gene responsible for the development of mixed
polyposity has not yet been identified. Analysis of link-
ages defined the region strictly bound to the appearance
of the morbid signs. This was termed CRAC1 and it is
located on chromosome 15, on its long arm. In a proband
in one of the families presented by Cao a heterozygous
mutation was disclosed, a deletion of 11 nucleotides in
exon 2 of the BMPR1A gene. In the remaining family
members the mutation could not be detected. Mixed
polyposis is the least recognised disease among the
hamartomatous polyposity syndromes and it still re-
quires further experimental studies, which would lead
to a rapid and simple diagnosis.
Care of patients with hamartomatous syndromes
Morbid syndromes linked to hamartomatous polyposities
form a rather heterogenous group both in respect to the
number and localization of polyps and the risk of cancer
development in the alimentary tract and other organs.
Even if the diseases are not among the most frequently
occurring ones they remain dangerous to patients not
only due to their predisposition to manifest themselves
as a neoplastic disease but also due to non-neoplastic
signs, such as haemorrhages, intussusception and ileus.
Every hamartomatous polyposis syndrome manifests its
own organ-specific localization of /symptom manifest-
ation and, consequently , each of them requires a dif-
ferent strategy of diagnostic management. Therefore,
an accurate qualification of the patients to a specific
morbid syndrome represents a basic step towards the
appropriate care of patients affected by the predisposi-
tions. Recommendations related to diagnostic studies
in hamartomatic polyposities are based only on the
opinions of experts. To date, no randomised diagnostic
studies have been conducted on the efficacy of medical
care programmes in the diseases [47]. For Peutz -
Jeghers syndrome diagnostic care is directed to the
organs endangered with neoplastic transformation which
vary depending on the gender of the patient. In both
males and females examination of the small bowel is
recommended (small intestine passage) beginning at the
8th year of age, every two-three years. Reports are avail-
able on the advantageous role of capsule endoscopy but
the number of tests that have been performed is still insuf-
ficient to recommend the approach in the form of man-
agement recommendations [48]. Extensive diagnostic and
therapeutic hopes may be founded on double-balloon en-
doscopy, allowing unitemporal polypectomies in necessarycases [49]. Colonoscopy is recommended every 2–3 years
up to the 18th year of life. It should be stressed that
endoscopic surveillance with regular polypectomies
seem to effectively safeguard the patients from the de-
velopment of malignant tumours [50].
Beginning at the 24th year of age it is also recommend
to subject the patient every 1–2 years to a USG examin-
ation of the pancreas. In women the tests include monthly
self-examination of breasts from 18 years of age onwards
and an according to international guidelines for hereditary
breast cancer, annual breast ultrasound and MRI from
age 25 and annual mammography from age 35 [8,47].
The ovaries should be examined once a year between
birth and the 12th year of age and, then, from the 21st
year of age. In male patients testes should be tested
from birth till the 12th year of age [47,51]. In juvenile
polyposity the care of patients focuses on monitoring
the alimentary system. However, in a few families co-
manifestation of a haemorrhagic angiomatosis has been
observed in cases of mutations in the SMAD4 so the
potential for aberrant vascular development should be
taken into account. Attention should be paid to the
occurrence of heamorrhages, anaemia, abdominal pains,
diarrhea and alterations in the shape or colour of foeces
in the patients. Manifestation of such alterations in-
dicates the necessity of performing additional studies,
including colonoscopy. In asymptomatic patients endo-
scopic tests (gastroduodenoscopy and colonoscopy) should
be conducted beginning from the 15th year of age. If
endoscopy discloses the presence of polyps they should
be removed and, in such a situation the test should be
repeated and polyps should be removed every year
[47]. If no polyps are detected the test may be repeated
once every three years. In mixed polyposity endoscopic
examination of the large bowel is recommended once
a year and the diagnosed polyps should be removed by
polypectomy [51,52]. Cowden’s syndrome carries the
risk of a neoplastic disease in various organs, therefore,
prophylactic examinations should include the thyroid
gland, the breasts and endometrium. No specific recom-
mendations are available for testing the alimentary tract
but certain authors recommend a periodical examination
of the tract with radiologic studies [3,47,53]. Examination
of the breasts bay self-examination conducted once a
month and annual breast ultrasound and MRI should
begin at the 30th year. The annual mammography should
be performed from age 35. Thyroid USG examination
should be supplemented with an aspiration thin-needle
biopsy of detected tumours [3,53].
The basic method in the care of patients with the
above polyposis syndromes involves an endoscopic sur-
veillance with the regular removal of qualifying polyps
(large, with macroscopic signs of malignancy, contact
or spontaneous bleeding). In cases of a severe course,
Stojcev et al. Hereditary Cancer in Clinical Practice 2013, 11:4 Page 8 of 9
http://www.hccpjournal.com/content/11/1/4with a high number of rapidly growing polyps in the
colon, a colectomy with ileo-rectal anastomosis may
be recommended [3]. If a great number of polyps, dif-
ficult to remove, develop in the rectum, restorative
proctocolectomy should be considered.
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